Aventura Private Wealth LLC Acquires Shares of 13,296 Bristol Myers Squibb Company $BMY

Aventura Private Wealth LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,296 shares of the biopharmaceutical company’s stock, valued at approximately $717,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $25,000. Harbor Capital Advisors Inc. raised its position in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 313 shares during the period. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Bristol Myers Squibb in the third quarter valued at approximately $35,000. JPL Wealth Management LLC purchased a new position in Bristol Myers Squibb during the third quarter valued at $36,000. Finally, Total Investment Management Inc. acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth about $38,000. 76.41% of the stock is currently owned by institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. and EMA approvals expanded Opdivo’s use into frontline Stage III/IV classical Hodgkin’s lymphoma for patients 12+, strengthening BMY’s oncology franchise and near‑term revenue potential. Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo US FDA approves Bristol Myers Squibb’s cancer drug for Hodgkin’s lymphoma
• Positive Sentiment: Sotyktu (BMY) received a label expansion into psoriatic arthritis, broadening BMY’s immunology franchise and helping offset pressure from legacy oncology and cardiovascular patent cliffs. Will the Recent Label Expansion of BMY’s Sotyktu Boost Its Prospects?
• Positive Sentiment: BMY advanced its protein‑degradation program: first‑in‑human dosing of BMS‑986506 for clear cell renal cell carcinoma triggered a $10M milestone to Evotec, signaling pipeline progress and potential long‑term upside if early data read out well. Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration
• Neutral Sentiment: HSBC nudged its price target to $60, a modest analyst upgrade that signals some confidence but is unlikely to drive large near‑term moves on its own. HSBC Boosts Bristol Myers Squibb (NYSE:BMY) Price Target to $60.00
• Neutral Sentiment: BMY scheduled Q1 2026 results for April 30 — a near‑term event that could reprice the stock depending on revenue and EPS versus guidance/expectations. Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
• Neutral Sentiment: Coverage pieces (Schaeffer, Zacks) have highlighted BMY as a recommended pick or trending ticker, which can lift interest but may already be priced in. Top Stock Picks of 2026: Bristol-Myers Squibb Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
• Negative Sentiment: Technical weakness flagged by a potential “death cross” (50‑day moving average crossing below 200‑day) can prompt selling by trend‑followers and contributed to the down‑pressure. These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Bristol Myers Squibb Stock Down 1.2%

Shares of NYSE BMY opened at $57.42 on Friday. The firm’s 50-day moving average is $58.60 and its two-hundred day moving average is $51.81. The company has a market capitalization of $116.93 billion, a PE ratio of 16.64, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the company posted $1.67 EPS. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Analyst Ratings Changes

A number of research firms have weighed in on BMY. Piper Sandler reissued an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. UBS Group restated a “buy” rating and set a $70.00 price target on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Morgan Stanley reiterated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $61.41.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.